SRPK1 promotes cell proliferation and tumor growth of osteosarcoma through activation of the NF-κB signaling pathway
Author:
Gong Yubao1ORCID, Yang Chen1, Wei Zhengren2, Liu Jianguo1
Affiliation:
1. Department of Orthopedics , The First Hospital of Jilin University , No. 1 Xinmin Street , Changchun 130021 , China 2. Department of Pharmacology , Basic Medical School, Jilin University , Changchun , China
Abstract
Abstract
To explore the expression and the functions of SRPK1 in osteosarcoma, we retrieved transcription profiling dataset by array of human bone specimens from patients with osteosarcoma from ArrayExpress (accession E-MEXP-3628) and from Gene Expression Omnibus (accession GSE16102) and analyzed expression level of SRPK1 and prognostic value in human osteosarcoma. Then we examined the effect of differential SRPK1 expression levels on the progression of osteosarcoma, including cell proliferation, cell cycle, apoptosis, and investigated its underlying molecular mechanism using in vitro osteosarcoma cell lines and in vivo nude mouse xenograft models. High expression level of SRPK1 was found in human osteosarcoma tissues and cell lines as compared to the normal bone tissues and osteoblast cells, and predicted poor prognosis of human osteosarcoma. Overexpression of SRPK1 in osteosarcoma U2OS cells led to cell proliferation but inhibition of apoptosis. In contrast, knockdown of SRPK1 in HOS cells impeded cell viability and induction of apoptosis. Moreover, silencing SRPK1 inhibited osteosarcoma tumor growth in nude mice. Mechanistic studies revealed that SRPK1 promoted cell cycle transition in osteosarcoma cells and activation of NF-κB is required for SRPK1 expression and its pro-survival signaling. SRPK1 promoted human osteosarcoma cell proliferation and tumor growth by regulating NF-κB signaling pathway.
Publisher
Walter de Gruyter GmbH
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference43 articles.
1. Amin, E.M., Oltean, S., Hua, J., Gammons, M.V., Hamdollah-Zadeh, M., Welsh, G.I., Cheung, M.K., Ni, L., Kase, S., Rennel, E.S., et al.. (2011). WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20: 768–780, https://doi.org/10.1016/j.ccr.2011.10.016. 2. Bielack, S.S., Kempf-Bielack, B., Delling, G., Exner, G.U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al.. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20: 776–790, https://doi.org/10.1200/jco.2002.20.3.776. 3. Bielli, P., Bordi, M., Di Biasio, V., and Sette, C. (2014). Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative 5′ splice site selection. Nucl. Acids Res. 42: 12070–12081, https://doi.org/10.1093/nar/gku922. 4. Catz, S.D. and Johnson, J.L. (2001). Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20: 7342–7351, https://doi.org/10.1038/sj.onc.1204926. 5. Chang, Y., Wu, Q., Tian, T., Li, L., Guo, X., Feng, Z., Zhou, J., Zhang, L., Zhou, S., Feng, G., et al.. (2015). The influence of SRPK1 on glioma apoptosis, metastasis, and angiogenesis through the PI3K/Akt signaling pathway under normoxia. Tumour Biol. 36: 6083–6093, https://doi.org/10.1007/s13277-015-3289-2.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|